Journal article
Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study
Abstract
About half of the patients who initiate therapy with mepolizumab discontinue treatment within the first or second year. Concomitant use of short-acting β2-agonists and oral corticosteroids drops during mepolizumab use. https://bit.ly/3aRISqS.
Authors
Lee JK; Gendron A; Knutson M; Sriskandarajah N; Mbuagbaw L; Noorduyn SG
Journal
ERJ Open Research, Vol. 7, No. 1, pp. 00778–02020
Publisher
European Respiratory Society (ERS)
Publication Date
January 2021
DOI
10.1183/23120541.00778-2020
ISSN
2312-0541